Cargando…
In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial
Extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales continue to pose a major threat to human health worldwide. Given the limited therapeutic options available to treat infections caused by these pathogens, identifying additional effective antimicrobials or revisiting existing drugs is...
Autores principales: | Stewart, Adam G., Cottrell, Kyra, Henderson, Andrew, Vemuri, Kanthi, Bauer, Michelle J., Paterson, David L., Harris, Patrick N. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552722/ https://www.ncbi.nlm.nih.gov/pubmed/34232101 http://dx.doi.org/10.1128/spectrum.00226-21 |
Ejemplares similares
-
Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis
por: Vance, Mary Kathryn, et al.
Publicado: (2023) -
Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections
por: Ranasinghe, Ama, et al.
Publicado: (2022) -
Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial
por: Stewart, Adam G, et al.
Publicado: (2021) -
The Characteristics of Extended-Spectrum β-Lactamases (ESBLs)-Producing Escherichia coli in Bloodstream Infection
por: Li, Rongrong, et al.
Publicado: (2023) -
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
por: Harris, Patrick NA, et al.
Publicado: (2015)